Finance
AstraZeneca Says It Will Build Cell Therapy Base, Innovation Centre in Shanghai
Published by Global Banking & Finance Review®
Posted on March 19, 2026
2 min readLast updated: March 19, 2026
Quick Summary
AstraZeneca is set to build a cell‑therapy manufacturing and innovation centre in Shanghai, positioning itself as the first global drugmaker in China with end‑to‑end CAR‑T therapy capabilities, leveraging its 2024 acquisition of Gracell and its existing R&D hubs.
AstraZeneca says it will build cell therapy base, innovation centre in Shanghai
Expansion of AstraZeneca’s Cell Therapy and Innovation Capabilities in China
Overview of the New Facilities
SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-end cell therapy capabilities in China.
Purpose and Scope of the Cell Therapy Facility
The cell therapy facility will be used to manufacture and supply CAR‑T cell therapies for China and other Asian markets, the UK drugmaker said in a statement published on its Chinese social media account.
Understanding CAR-T Therapies
CAR-T therapies modify a patient's immune cells to recognise a specific target and destroy cancer cells.
Investment Strategy and Market Expansion
Details of AstraZeneca’s Investment in China
A spokesperson for AstraZeneca told Reuters that the cell therapy investment is part of its plan to invest $15 billion in China through 2030 to expand its medicine manufacturing and research and development segments, announced in January, but declined to break down its specific value.
Global Investment Context
Even as AstraZeneca invests heavily in the United States, led by a $50 billion manufacturing deal last year, it continues to build its business in its second-biggest market after scandals, including the arrest of its China president in 2024.
Track Record of AstraZeneca’s Investments in China
AstraZeneca has invested billions of dollars in the country in Pascal Soriot's tenure as CEO since 2012, including $2.5 billion in a Beijing research and development hub in March last year, its second after a Shanghai site opened in 2024.
Reporting Credits
(Reporting by Andrew Silver in Shanghai and Beijing Newsroom; Editing by Tom Hogue and Janane Venkatraman)
Key Takeaways
- •The new Shanghai facility will handle autologous CAR‑T cell therapy manufacturing and supply for China and broader Asian markets, completing the full cell‑therapy value chain in‑country.
- •This move builds on AstraZeneca’s 2024 acquisition of Gracell Biotechnologies and complements its global strategic R&D centres in Beijing and Shanghai, which collaborate with over 500 hospitals.
- •The initiative is part of a broader US$15 billion investment through 2030 in China across R&D, manufacturing, and innovation—supporting expansion in cell therapies and radioconjugates, and increasing AstraZeneca’s China workforce beyond 20,000.
Frequently Asked Questions about AstraZeneca says it will build cell therapy base, innovation centre in Shanghai
1What facility will AstraZeneca build in Shanghai?
AstraZeneca will build a cell therapy manufacturing and supply base as well as an innovation centre in Shanghai.
2What is the goal of AstraZeneca's new facility in China?
The goal is to become the first global drugmaker with end-to-end cell therapy capabilities in China.
3Which therapies will be produced at AstraZeneca's Shanghai facility?
The facility will manufacture and supply autologous CAR‑T cell therapies for China and other Asian markets.
